Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.

摘要: This article reviews recent developments with the use of adjuvant chemotherapy for resected early-stage non-small cell lung cancer (NSCLC) and implications these healthcare in New Zealand (NZ). Non-small is a major cause mortality morbidity NZ, greatly over-represented among Maori socioeconomically deprived populations. Early-stage NSCLC potentially curable by surgery, but long-term outcome after surgical resection limited disease recurrence locally or at sites distant from primary disease. Three large randomised controlled phase III trials using modern platinum-based combination protocols have shown significant survival benefits postoperative NSCLC. Cisplatin plus vinorelbine was used as regimen two resulting improvements 5-year 51.2% versus 42.6% (p=0.013) 69% 54% (p=0.03), respectively. In expected to prevent up 15 deaths each year relatively low drug expenditure has potential benefit economically-deprived disproportionately more than other conclusion, it opinion this group NZ specialists that cisplatin should now be adopted standard care patients stage II For occur, current PHARMAC policies preventing its eligible will need revised.